Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Expands By 44.9%

Posted by Defense World Staff on Mar 18th, 2025

Windtree Therapeutics, Inc. (NASDAQ:WINT – Get Free Report) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 83,000 shares, an increase of 44.9% from the February 13th total of 57,300 shares. Currently, 11.1% of the shares of the company are short sold. Based on an average daily trading volume, of 318,400 shares, the days-to-cover ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $350.00 target price on shares of Windtree Therapeutics in a report on Wednesday, December 4th.

View Our Latest Analysis on WINT

Windtree Therapeutics Price Performance

Shares of Windtree Therapeutics stock opened at $1.92 on Tuesday. The stock has a fifty day moving average price of $6.72 and a 200-day moving average price of $44.78. The firm has a market cap of $1.44 million, a PE ratio of -0.12 and a beta of 0.68. Windtree Therapeutics has a 1 year low of $1.78 and a 1 year high of $737.44.

Institutional Trading of Windtree Therapeutics

A hedge fund recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC purchased a new position in Windtree Therapeutics, Inc. (NASDAQ:WINT – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned 1.08% of Windtree Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 29.33% of the company’s stock.

About Windtree Therapeutics

(Get Free Report)

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.